Carol Lynch

Carol Lynch was appointed President, Sandoz US, Head of North America in March 2018. In this role, Carol leads Sandoz’ largest commercial and country organization – the United States – which is responsible for over 35% of Sandoz’ global revenue. Carol also oversees Sandoz’ commercial operations in Canada. She is a member of the Sandoz Executive Committee. Carol is the Vice Chair and board member of the Association for Accessible Medicines (AAM) in the US, and also serves as Chair of the Biosimilar Medicines Group, a Medicines for Europe sector group, and will continue to do so until her committed term is over.<br/>

Prior to this role, Carol was the Global Head of Biopharmaceuticals at Sandoz, responsible for the development, manufacturing and commercialization of biosimilars, including its contract manufacturing business. In her four years in this role, Carol grew the biopharma business reaching 1bn USD in sales annually, and delivered a portfolio with five biosimilar approvals. Under Carol’s leadership, Sandoz achieved the first approval and launch of a biosimilar in the US, and saw the launch of the next wave of biosimilars in the EU. Prior to joining Sandoz in 2014, Carol held a number of Commercial and Development leadership positions in Novartis Pharmaceuticals both globally and in country organizations, including the United States.<br/>

Carol has more than 25 years of global pharmaceutical and generics industry experience.<br/>